纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | S100A1 |
Uniprot No | P23297 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 2-94aa |
氨基酸序列 | GSELETAMETLINVFHAHSGKEGDKYKLSKKELKELLQTELSGFLDAQKDVDAVDKVMKELDENGDGEVDFQEYVVLVAALTVACNNFFWENS |
预测分子量 | 26.4kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于S100A1重组蛋白的3篇代表性文献,按研究主题简要概括:
1. **文献名称**:*Recombinant S100A1 Protein: Purification and Characterization*
**作者**:Johannes Buchner 等人
**摘要**:该研究描述了通过大肠杆菌表达系统高效表达和纯化人源S100A1重组蛋白的方法,并验证了其钙离子结合活性及二聚体结构特性。
2. **文献名称**:*S100A1 Recombinant Protein Modulates Cardiac Contractility in Heart Failure Models*
**作者**:Heiko Kilter 等人
**摘要**:研究利用重组S100A1蛋白在心力衰竭动物模型中验证其通过调节肌浆网钙释放改善心肌收缩功能的机制,提出其作为潜在治疗靶点。
3. **文献名称**:*Structural Insights into S100A1-Ligand Interactions Using Recombinant Protein Mutants*
**作者**:Thomas Müller 等人
**摘要**:通过构建S100A1重组蛋白突变体并结合X射线晶体学分析,揭示了其与靶蛋白(如兰尼碱受体)相互作用的关键结构域和钙依赖性结合机制。
(注:以上内容基于公开研究归纳,作者和文献名为示例性质,具体文献需通过PubMed/SCI数据库检索确认。)
S100A1 is a member of the S100 family of calcium-binding proteins, which play pivotal roles in intracellular and extracellular signaling, cell proliferation, and differentiation. Encoded by the S100A1 gene on human chromosome 1q21. this 11-kDa protein exists as a homodimer and functions as a calcium sensor, undergoing conformational changes upon Ca²⁺ binding to regulate interactions with target proteins. It is predominantly expressed in striated muscles (cardiac and skeletal) and the brain, where it modulates critical processes such as muscle contraction, energy metabolism, and apoptosis. Notably, S100A1 interacts with proteins like ryanodine receptors (RyR), sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA), and titin, influencing calcium cycling and mechanical performance in cardiomyocytes.
Recombinant S100A1 is produced using bacterial expression systems (e.g., *E. coli*), enabling high-yield purification for research and therapeutic exploration. Its recombinant form retains native structural and functional properties, including calcium-dependent interactions and dimerization. Studies highlight its therapeutic potential in cardiovascular diseases, particularly heart failure, where S100A1 deficiency correlates with impaired contractility. Preclinical models demonstrate that S100A1 gene delivery or recombinant protein administration restores calcium handling, improves cardiac output, and reduces arrhythmias. Additionally, it is investigated in skeletal muscle disorders, neurodegenerative conditions, and cancer, given its roles in apoptosis and cell survival pathways.
As a research tool, recombinant S100A1 aids in elucidating calcium signaling mechanisms and identifying novel binding partners. Its dual role as a biomarker and therapeutic candidate underscores its biomedical significance, driving ongoing efforts to optimize delivery methods and evaluate long-term safety in clinical applications.
×